Change of Stock Abbreviation and Logo | Transcenta Holding-B Officially Renamed as Transcenta Pharmaceutical-B

Princeton, New Jersey, USA, and Suzhou, China, April 9, 2026 — Transcenta Pharmaceutical (06628.HK), an international biopharmaceutical company in the clinical stage with integrated capabilities in biologic drug discovery, development, process development, and production, announced that its new logo will be officially launched on April 8. The Chinese stock abbreviation will change from 'Transcenta Holding-B' to 'Transcenta Pharmaceutical-B' starting April 13, 2026. The English stock abbreviation, company name, and stock code on the Hong Kong Stock Exchange will remain unchanged.

The change of the stock abbreviation aims to more clearly communicate the company's positioning to the market and strengthen its recognition as a pharmaceutical enterprise focused on the biomedicine sector. This will help all stakeholders better understand the company’s business direction and development priorities. This adjustment is also in line with the company’s mission to 'develop high-quality innovative biopharmaceuticals using cutting-edge technology, and provide differentiated, affordable products to benefit patients worldwide.' To align with corporate image consistency, the company has simultaneously updated its logo. The new logo will be printed on relevant corporate documents, including but not limited to interim and annual reports, announcements, circulars, notices, share certificates, and press releases, and will be displayed on the company’s official website.

Original logo

Current logo

This adjustment clearly conveys Transcenta Pharmaceutical's firm commitment to深耕the biopharmaceutical field and more accurately reflects the company’s integrated capabilities based on its three core technology platforms, which support its core business and future development strategy. These three platforms include the Immune Tolerance Breakthrough (IMTB) technology platform, the Highly Integrated Continuous Bioprocessing (HiCB) platform, and the Site-Specific Antibody Conjugation for Engineering Radiopharmaceuticals (SEAR) platform.

Leveraging these platforms, Transcenta Pharmaceutical is advancing the global development and commercialization of a diversified product pipeline. Key programs include osemitamab (TST001) for the treatment of gastric or gastroesophageal junction adenocarcinoma and other solid tumors, and blosozumab (TST002) for the treatment of osteoporosis. In addition, the company is developing dozens of novel biologics covering both oncology and non-oncology indications, including orthopedics, autoimmune diseases, and renal conditions.

The change of the stock abbreviation and company logo will not affect any rights of the existing holders of the company’s securities, nor will it impact the group’s daily business operations or financial condition. All issued share certificates bearing the old company logo will continue to serve as valid proof of ownership for the company’s shares and will remain effective for trading, settlement, registration, and delivery purposes. The company will not arrange for the free replacement of existing share certificates with new ones bearing the updated logo.

About Transcenta

Transcenta is a clinical-stage biopharmaceutical company with comprehensive capabilities in biologic drug discovery, research and development, process development, and production.

Headquartered in Suzhou, Transcenta has successfully established a global business presence: it operates drug discovery, clinical, and translational research centers in Suzhou, a process and product development center and manufacturing facility in Hangzhou, and clinical development centers in China, the United States, and Europe. Transcenta is developing a diversified pipeline of dozens of novel biologics covering oncology and non-oncology indications, including orthopedics, autoimmune diseases, and kidney diseases.

For more information about Transcenta, please visit the company's website: www.transcenta.com or LinkedIn page: Transcenta. If you are interested in exploring capital cooperation opportunities with us, please feel free to reach out via ir@transcenta.com to discuss collaboration possibilities.

7688 Views